Webinar Bundle: FDA-Regulated Research

Overview

PRIM&R has developed and presented over 100 webinars, offering convenient, affordable, in-depth analysis on a range of important topics for professionals in the research ethics field.

The FDA-Regulated Research webinar bundle is made up of a curated selection of these high-quality on-demand recorded webinars. Developed and presented by experts, the webinars in this bundle offer insight into some of the fundamental concepts and challenges involved in FDA regulations. Webinar topics include the difference between FDA and DHHS regulations, ethical considerations in expanded access, and reviews of studies involving In-Vitro Diagnostics.

This webinar bundle may be accessed by individual PRIM&R members for $0 in the online store. Nonmembers may purchase the bundle in the online store. Groups who would like to purchase the bundle should complete the order form. The webinars included in this bundle are also available for purchase individually.

Continuing Education

CIP Credit labelWebinar viewers holding the Certified IRB Professional (CIP®) credential may apply 1-1.5 continuing education credits from each webinar towards CIP recertification. This webinar bundle is eligible for a total of 6 continuing education credits. Learn More »

Webinars

Please see below for descriptions and learning objectives of each webinar in this bundle.

Expanded Access: Ethical and Regulatory Issues for Investigational Drugs and Devices

On-Demand Webinar Recording, 2010

Speakers: George Gasparis, CIP and Richard Klein

In this webinar, speakers provide an overview of the complex policies that govern expanded access programs involving both investigational drugs and devices.

Presented by expert faculty representing both the regulatory and institutional perspectives, this webinar:

  • Broadens attendees' understanding of expanded access programs and how they differ from clinical research
  • Explores the ethical and regulatory implications of expanded access programs for IRBs, patients, healthcare providers and researchers
  • Teaches views how to interpret and apply investigational drug and investigational device regulations regarding expanded access
  • Advances attendees' thinking about, and management of, these complex issues

Participation in this 90-minute webinar counts as 1.5 CE credit hours.

Purchase Expanded Access: Ethical and Regulatory Issues for Investigational Drugs and Devices webinar recording only.

FDA Oversight and IRB Review of Studies that Include In-Vitro Diagnostics

On-Demand Webinar Recording, 2015

Speakers: Jonathan M. Green, MD and E. David Litwack, PhD

IVD products are medical devices or biological products intended to diagnose disease or determine a state of health. The US Food and Drug Administration (FDA) regulates investigations involving IVDs under the investigational device exemption (IDE). To support this work, IRBs must recognize when a study is using an IVD that is investigational, and determine whether it meets the criteria for an exempt device, a non-significant risk (NSR) device, or a significant risk (SR) device.

The rapid growth and application of genomic testing in clinical trials and the use of IVDs to select patients for drug trials, in particular, pose unique challenges for IRBs and investigators in this regard. IRBs, investigators, and sponsors often struggle with correctly identifying when an IVD is being used in a manner that makes it investigational, and correctly determining the risk level for the device.

During this webinar, presenters:

  • Provide an overview of FDA regulatory framework in relation to IVDs
  • Explain the application of IDE regulations to studies with IVDs
  • Highlight complex IRB scenarios and share processes developed by one institution through the use of case studies

Participation in this 90-minute webinar counts as 1.5 CE credit hours.

Purchase FDA Oversight and IRB Review of Studies that Include In-Vitro Diagnostics webinar recording only.

DHHS and FDA Regulations: What's Different, What's Similar, and What Does it all Mean for my HRPP?

On-Demand Webinar Recording, 2011

Speakers: Lisa Buchanan, MAOM and Richard Klein

DHHS and FDA Regulations: What’s Different, What’s Similar, and What Does it all Mean for my HRPP? features a discussion between the representatives of these two federal agencies.

Topics include:

  • Background information about the reasons for, and historical underpinnings of, the two sets of federal regulations
  • Overview of the U.S. Department of Health and Human Services (DHHS) regulations and recent guidance documents, including how they apply to research conducted internationally
  • Areas of overlap and divergence between the regulations of DHHS and the US Food and Drug Administration (FDA), and guidelines for determining which are applicable to the different kinds of research conducted at your institution

Participation in this 90-minute webinar counts as 1.5 CE credit hours.

Purchase DHHS and FDA Regulations: What's Different, What's Similar, and What Does it all Mean for my HRPP? webinar recording only.

Investigator-Initiated Device Studies: How IRBs Can Help Researchers Work With the FDA

On-Demand Webinar Recording, 2014

Speakers: Owen Faris, PhD, Soma Kalb, PhD, and Matthew Wladkowski, MS, RAC

US Food and Drug Administration (FDA) approval of an investigational device exemption (IDE) is required for studies of significant risk devices that involve human subjects and are not approved or cleared for the indication being studied. The process of applying for an IDE can be challenging for institutional review boards (IRBs) and investigators.

In most academic centers, investigators rely on IRBs for guidance with the IDE submission and approval process. This webinar provides the tools for determining whether an IDE is necessary, charting a timeline for the application process, and identifying the respective responsibilities of investigators and IRBs. The webinar covers the following topics:

  • Is an IDE needed?
    To assist the investigator in making this determination, the IRB needs to understand the goals of the study and whether the proposed research presents significant risk.
  • Application process
    If it is determined that an IDE is needed, IRB review must focus on the unique characteristics of device studies. Presenters highlighted the distinctions between device and drug studies as they pertain to IRB and FDA review, and identify key pieces of information that investigators need to present to the IRB and/or include in an IDE submission to FDA.
  • Deciphering the FDA decision letter
    The FDA decision letter will fully approve, approve with conditions, or disapprove the IDE. Presenters reviewed each of these potential decisions and offer insight into their implications.
  • Role of the IRB in the subsequent steps
    If the IDE is approved with conditions or disapproved, FDA’s decision letter will ask the investigator to respond to certain questions. If the IDE is fully approved, the sponsor may begin enrollment in the study without being subject to such requirements. The presenters discussed how IRBs can assist investigators in preparing responses to FDA as well as in successfully initiating the IDE study.

Participation in this 90-minute webinar counts as 1.5 CE credit hours.

PurchaseInvestigator-Initiated Device Studies: How IRBs Can Help Researchers Work With the FDA webinar recording only.

Fees

Individual members may access these complimentary bundles for $0 in the online store. Nonmembers can purchase the bundle or an individual webinar in the online store. Members and nonmembers looking to purchase a group registration should complete the order form. Not a PRIM&R member? Join online now!

Webinar Individual Member Fee Group Member Fee Individual Nonmember Fee Group Nonmember Fee
Expanded Access: Ethical and Regulatory Issues for Investigational Drugs and Devices $0 $300 $175 $375
FDA Oversight and IRB Review of Studies that Include In-Vitro Diagnostics $0 $325 $200 $400
DHHS and FDA Regulations: What's Different, What's Similar, and What Does it all Mean for my HRPP? $0 $300 $175 $375
Investigator-Initiated Device Studies: How IRBs Can Help Researchers Work With the FDA $0 $325 $200 $400
Totals $0
Purchase Online
$1,250
Download the order form (PDF)
$750
Purchase Online
$1,550
Download the order form (PDF)

Questions?

Review our webinar FAQs

for information about policies, CE credit, technical requirements, and webinar recordings

Please email webinars@primr.org if you have additional questions.